2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2640

Can GP88 (Progranulin) be Used to Predict the Efficacy of Infliximab?

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2381

Canakinumab Monotherapy for the Treatment of Majeed Syndrome. Five-Year Experience

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2327

Cardiac Involvement in Inflammatory Myopathies: A Report from the Remicam Registry

Muscle Biology, Myositis and Myopathies - Poster II: Clinical

9:00AM-11:00AM: Abstract Number: 2097

Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients

Antiphospholipid Syndrome - Poster II

9:00AM-11:00AM: Abstract Number: 2293

Cardiometabolic Risk and Subclinical Urate Deposits in Patients with Symptomatic Hyperuricemia and Metabolic Syndrome

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2170

Cardiovascular Risk in Patients with Psoriasis, Psoriatic and Rheumatoid Arthritis: A Prospective Study Using Secured Anonymised Information Technology Databank in Wales, United Kingdom

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2611

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2437

Causes of Cesarean Section and Labor Induction in Systemic Lupus Erythematosus and Rheumatoid Arthritis Pregnancies

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2136

CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model

Biology and Pathology of Bone and Joint - Poster I

9:00AM-11:00AM: Abstract Number: 2874

CD16+monocytes Are Enriched and Functionally Exacerbated in Driving B Cell Activation Under Systemic Lupus Erythematosus Condition

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2882

CD4+ T Helper Cells and Regulatory T Cells in Active Lupus Nephritis – an Imbalance Towards a Predominant Th1 Response?

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2421

Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2800

Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2884

Cell-Type Specific Epigenetic Features of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2231

Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis

Health Services Research - Poster III

«Previous Page
1
…
7
8
9
10
11
…
69
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.